Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Schedule of Reportable Segments

The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands):

Segment Information

Year Ended December 31, 2021	Finance Receivables			Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	39,310		$	16,122		$	—		$	55,432
Other revenue		—			723			—			723
Interest expense		374			—			—			374
Manufacturing, research and development		—			7,347			—			7,347
Depreciation and amortization expense		—			4,055			6			4,061
Change in fair value of acquisition-related contingent consideration		—			(287	)		—			(287	)
General and administrative		1,813			3,983			7,824			13,620
Other income, net		1,971			—			—			1,971
Income tax expense		—			—			7,082			7,082
Consolidated net income (loss)		39,094			1,747			(14,912	)		25,929
Year Ended December 31, 2020	Finance Receivables			Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	30,800		$	5,903		$	—		$	36,703
Other revenue		8			—			1			9
Provision for credit losses and impairment expense		163			—			—			163
Interest expense		455			—			—			455
Manufacturing, research and development		—			4,268			—			4,268
Depreciation and amortization expense		—			12,081			10			12,091
Change in fair value of acquisition-related contingent consideration		—			4,400			—			4,400
General and administrative		736			3,875			5,935			10,546
Other (expense) income, net		(1,201	)		—			77			(1,124	)
Income tax benefit		—			—			(1,537	)		(1,537	)
Consolidated net income (loss)		28,253			(18,721	)		(4,330	)		5,202